Presented at #ESCCongress:
In patients with ST-segment elevation myocardial infarction, immediate multivessel PCI was noninferior to staged multivessel PCI with respect to the risk of death and adverse cardiovascular events at 1 year.
Full results of the MULTISTARS AMI trial:
Late breaking at #ESCCongress:
In a randomized trial involving patients with advanced heart failure and atrial fibrillation, catheter ablation decreased the risk of cardiovascular events at a median of 18 months.
Read the full CASTLE HTx trial results: https://t.co/g0Hjnqoypi
#ESCCongress#hotline
ATTRibute Trial: acoramidis in TRC
♥️RCT ATTR-CM+ class I-III, mostly male
♥️⤵️ all cause ☠️ , HF 🏥with acoramidis tx
♥️results consistent across subgroups
♥️better QOL with tx, TTR stable, ⤴️6MWD
♥️ safe well tolerated
Driving home #HFpEF 🫀obesity phenotype:
1️⃣⬆️comobidities = ⬆️inflammation
2️⃣⬆️☠️morbidity and 💨symptoms
3️⃣📋@escardio guidelines recommend SGLT2i (class1a)
4️⃣💪🏼evidence for GLP1RA to improve KCCQ, 6MWT, & ⬇️NT pro BNP
@CanHFSociety#ESC2023
Excellent summary of established & upcoming trials re: timing of #AS intervention. Awaiting results for what to do with:
1️⃣Severe AS w/o guideline criteria (Early TAVR, EXPAND TAVR II)
2️⃣Moderate AS w/ #HF (TAVR Unload, PROGRESS)
@escardio#ESC2023
STEP HFpEF #hotline#ESCCongress#HFpEF#semaglutide RCT
♥️EF 57%, >50% 💃🏻
♥️few on SGLT2i
♥️improved QOL + body weight
♥️⬆️ 6 min walk ⬇️ CRP ⬇️ BNP ⬇️ HF
🎯 Semaglutide as a tx for HFpEF💥